✦ LIBER ✦

248: Novel tyrosine kinase inhibitor therapy (NTKI) prior to allogeneic stem cell transplantation (ASCT) in patients with chronic myeloid leukemia (CML): No evidence for increased transplant-related toxicity

✍ Scribed by E. Jabbour; J. Cortes; H. Kantarjian; S. Giralt; R. Champlin; M. de Lima

Book ID: 116279429
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 53 KB
Volume: 13
Category: Article
ISSN: 1083-8791
DOI: 10.1016/j.bbmt.2006.12.253

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Novel tyrosine kinase inhibitor therapy

Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia : No evidence for increased transplant-related toxicity

✍ Elias Jabbour; Jorge Cortes; Hagop Kantarjian; Sergio Giralt; Borje S. Andersson 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 72 KB 👁 1 views

## Abstract ## BACKGROUND. Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for chronic myeloid leukemia (CML) are increasingly likely to have received a novel tyrosine kinase inhibitor (NTKI) after failing imatinib mesylate. It is unknown whether the use of these NTKI

The Decision to Offer Allogeneic Stem Ce

The Decision to Offer Allogeneic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia in the Tyrosine Kinase Inhibitor Era

✍ Goldman, John M. 📂 Article 📅 2006 🏛 CIG Media Group, LP. 🌐 English ⚖ 66 KB